IP Library Granted Patent US 8,975,247
Granted Patent B2
US 8,975,247 · App. 13/376,483 · Granted Mar 10, 2015

Methods and compositions of treating a flaviviridae family viral infection

Inventors: Ingrid C. Choong (Los Altos, CA); David Cory (Redwood City, CA); Jeffrey S. Glenn (Palo Alto, CA); Wenjin Yang (Foster City, CA)
Assignee: The Board of Trustees of the Leland Stanford Junion University
A61K31/4184A61K31/437A61K31/4965A61K45/06C07D235/06C07D235/08C07D235/10C07D235/14C07D235/16C07D235/28C07D401/04C07D401/06C07D401/12C07D401/14C07D403/06C07D403/14C07D405/06C07D409/06C07D413/06C07D417/04C07D471/08C07D491/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,247
App. No.
13/376,483
Granted
Mar 10, 2015
Kind
B2
Abstract

Clemizole and clemizole analog compounds, and pharmaceutical compositions of the same, are useful in methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, and methods of treating liver fibrosis in a host.

Claims (26)

1. A compound having the structure shown in Formula III-C

or a pharmaceutically acceptable salt, a tautomer, or a prodrug thereof,

A 1 is a substituted or an unsubstituted, 5 or 6 membered, non aromatic heterocycle containing one basic nitrogen atom or a substituted or an unsubstituted 6 membered heteroaryl containing one basic nitrogen atom, wherein substituted refers to a substitution selected from the group consisting of: alkyl, alkenyl, oxo, aryl, heterocyclo, carbocyclo, halo, hydroxy, alkoxy, aryloxy, alkanoyl, aroyl, alkylester, arylester, cyano, nitro, amido, amino, substituted amino, lactam, urea, urethane, and sulfonyl;

wherein R 5 is a substituted or an unsubstituted C 1 -C 3 alkyl or 5 membered heteroaryl group, wherein substituted refers to a substitution selected from the group consisting of: aryl, heteroaryl, heterocyclo, carbocyclo, halo, hydroxy, protected hydroxy, alkoxy, acyl, aryloxy, alkylester, arylester, alkanoyl, aroyl, carboxy, protected carboxy, cyano, nitro, amino, substituted amino, (monosubstituted)amino, (disubstituted)amino, protected amino, amido, lactam, urea, urethane, and sulfonyl;

R 6 is hydrogen or a substituted or an unsubstituted C 1 -C 3 alkyl, wherein substituted refers to a substitution selected from the group consisting of: aryl, heteroaryl, heterocyclo, carbocyclo, halo, hydroxy, protected hydroxy, alkoxy, acyl, aryloxy, alkylester, arylester, alkanoyl, aroyl, carboxy, protected carboxy, cyano, nitro, amino, substituted amino, (monosubstituted)amino, (disubstituted)amino, protected amino, amido, lactam, urea, urethane, and sulfonyl; and

R 35 is hydrogen or a substituted or an unsubstituted C 1 -C 3 alkyl, wherein substituted refers to a substitution selected from the group consisting of: aryl, heteroaryl, heterocyclo, carbocyclo, halo, hydroxy, protected hydroxy, alkoxy, acyl, aryloxy, alkylester, arylester, alkanoyl, aroyl, carboxy, protected carboxy, cyano, nitro, amino, substituted amino, (monosubstituted)amino, (disubstituted)amino, protected amino, amido, lactam, urea, urethane, and sulfonyl.

2. A composition, comprising the following compound,

or a pharmaceutically acceptable salt, a tautomer, or a prodrug thereof.

3. A compound having the structure shown in Formula III-C

or a pharmaceutically acceptable salt, a tautomer, or a prodrug thereof,

wherein A 1 is a 6 membered, non aromatic heterocycle containing one basic nitrogen atom;

wherein R 5 is a C 1 -C 4 alkyl or 5 membered heteroaryl group;

wherein R 6 is hydrogen or a C 1 -C 4 alkyl; and

wherein R 35 is hydrogen or a C 1 -C 3 alkyl.

4. A compound having the structure shown in Formula III-C

or a pharmaceutically acceptable salt, a tautomer, or a prodrug thereof,

wherein A 1 is a 6 membered heteroaryl containing one basic nitrogen atom;

wherein R 5 is a C 1 -C 4 alkyl or 5 membered heteroaryl group;

wherein R 6 is hydrogen or a C 1 -C 4 alkyl; and

wherein R 35 is hydrogen or a C 1 -C 3 alkyl.

5. A compound having the structure shown in Formula III-C

or a pharmaceutically acceptable salt, a tautomer, or a prodrug thereof,

wherein A 1 is a 5 or 6 membered, non aromatic heterocycle containing one basic nitrogen atom or a 6 membered heteroaryl containing one basic nitrogen atom;

wherein R 5 is a C 1 -C 4 alkyl;

wherein R 6 is a C 1 -C 4 alkyl; and

wherein R 35 is a C 1 -C 3 alkyl.

Assignments (5)
CONFIRMATORY LICENSE Recorded May 11, 2017
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042446/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: GLENN, JEFFREY S.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 027810/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: CHOONG, INGRID C.
To: EIGER BIOPHARMACEUTICALS, INC.
Reel/Frame 027810/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: CORY, DAVID
To: EIGER BIOPHARMACEUTICALS, INC.
Reel/Frame 027810/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: YANG, WENJIN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; EIGER BIOPHARMACEUTICALS, INC.
Reel/Frame 027810/0228 →
Continuity (4)
Continuation In Part 12383030 · Mar 18, 2009
Continuation In Part 12383071 · Mar 18, 2009
Provisional Application 61299886 · Jan 29, 2010
Related Publication 20120276050A1 · Nov 1, 2012